Akebia Therapeutics (AKBA) Earnings Date, Estimates & Call Transcripts $2.06 +0.01 (+0.49%) (As of 11/27/2024 05:43 PM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Akebia Therapeutics Latest Earnings SummaryUpcoming Q4 Earnings DateMar. 13EstimatedActual EPS (Nov. 7) -$0.10 Missed By -$0.06 Consensus EPS (Nov. 7) -$0.04 Akebia Therapeutics issued Q3 2024 earnings on November 7, 2024, reporting an EPS of -$0.10, which missed the consensus estimate of -$0.04 by $0.06. Quarterly revenue was reported to be $37.43 million, below the consensus estimate of $45.66 million. With a trailing EPS of -$0.23, Akebia Therapeutics' earnings are expected to grow next year, from ($0.24) to ($0.18) per share. Conference Call TranscriptConference Call AudioAKBA Upcoming EarningsAkebia Therapeutics' next earnings date is estimated for Thursday, March 13, 2025, based off prior year's reporting schedules. Get Akebia Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Akebia Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataAKBA Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.AKBA Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad PacasoThe latest trend in real estateThese vacation homes are often expensive to maintain and vacant 90% of the year. But thanks to co-ownership, they’re being transformed into fully utilized assets. And there’s one company that’s leading the charge – already welcoming over 1,500 happy homeowners into their co-ownership family, earning $100M in gross profits along the way. Now, for the first time, this innovative company is opening its doors to public investors. Want to learn more about co-ownership and its potential? Check them out – but be aware: their share price is set to change December 5, so you don’t have long to maximize your stake.Don’t miss your chance to maximize your stake in this co-ownership revolution. Akebia Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241-$0.09-$0.09-$0.09Q2 20241-$0.07-$0.07-$0.07Q3 20241-$0.06-$0.06-$0.06Q4 20241-$0.04-$0.04-$0.04FY 20244-$0.26-$0.26-$0.26Q1 20251-$0.14-$0.14-$0.14Q2 20251-$0.13-$0.13-$0.13Q3 20251-$0.11-$0.11-$0.11Q4 20251-$0.05-$0.05-$0.05FY 20254($0.43)($0.43)($0.43) Akebia Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 3/13/2025(Estimated)------- 11/7/2024Q3 2024-$0.04-$0.10 -$0.06-$0.10$45.66M$37.43M 8/8/2024Q2 2024-$0.06-$0.04+$0.02-$0.04$45.61M$43.65M 5/9/2024Q1 2024-$0.09-$0.09--$0.09$41.13M$32.61M 3/14/2024Q4 2023-$0.04-$0.04--$55.64M$56.20M 11/8/2023Q3 2023-$0.09-$0.08+$0.01-$0.08$48.19M$42.05M 8/25/2023Q2 2023-$0.03-$0.06 -$0.03-$0.06$59.10M$56.38M The latest trend in real estate (Ad)These vacation homes are often expensive to maintain and vacant 90% of the year. But thanks to co-ownership, they’re being transformed into fully utilized assets. And there’s one company that’s leading the charge – already welcoming over 1,500 happy homeowners into their co-ownership family, earning $100M in gross profits along the way. Now, for the first time, this innovative company is opening its doors to public investors. Want to learn more about co-ownership and its potential? Check them out – but be aware: their share price is set to change December 5, so you don’t have long to maximize your stake.Don’t miss your chance to maximize your stake in this co-ownership revolution.5/8/2023Q1 2023-$0.15-$0.14+$0.01-$0.14$46.69M$40.13M 3/9/2023Q4 2022-$0.14-$0.04+$0.10-$0.04$48.35M$55.18M Akebia Therapeutics Earnings - Frequently Asked Questions When is Akebia Therapeutics's earnings date? Akebia Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 13th, 2025 based off last year's report dates. Learn more on AKBA's earnings history. Did Akebia Therapeutics beat their earnings estimates last quarter? In the previous quarter, Akebia Therapeutics (NASDAQ:AKBA) missed the analysts' consensus estimate of ($0.04) by $0.06 with a reported earnings per share (EPS) of ($0.10). Learn more on analysts' earnings estimate vs. AKBA's actual earnings. How can I listen to Akebia Therapeutics's earnings conference call? The conference call for Akebia Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Akebia Therapeutics's conference call transcript? The conference call transcript for Akebia Therapeutics's latest earnings report can be read online. Read Transcript How much revenue does Akebia Therapeutics generate each year? Akebia Therapeutics (NASDAQ:AKBA) has a recorded annual revenue of $194.62 million. How much profit does Akebia Therapeutics generate each year? Akebia Therapeutics (NASDAQ:AKBA) has a recorded net income of -$51.92 million. AKBA has generated -$0.23 earnings per share over the last four quarters. What is Akebia Therapeutics's EPS forecast for next year? Akebia Therapeutics's earnings are expected to grow from ($0.24) per share to ($0.18) per share in the next year. ` More Earnings Resources from MarketBeat Related Companies IMCR Earnings KNSA Earnings NRIX Earnings NTLA Earnings SNDX Earnings TVTX Earnings SYRE Earnings OCUL Earnings PRAX Earnings DAWN Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings Report The latest trend in real estate (Ad)These vacation homes are often expensive to maintain and vacant 90% of the year. But thanks to co-ownership, they’re being transformed into fully utilized assets. And there’s one company that’s leading the charge – already welcoming over 1,500 happy homeowners into their co-ownership family, earning $100M in gross profits along the way. Now, for the first time, this innovative company is opening its doors to public investors. Want to learn more about co-ownership and its potential? Check them out – but be aware: their share price is set to change December 5, so you don’t have long to maximize your stake.Don’t miss your chance to maximize your stake in this co-ownership revolution. This page (NASDAQ:AKBA) was last updated on 11/28/2024 by MarketBeat.com Staff From Our Partners25X predicted for “Amazon Coin” – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTop "Sleeping Giant" Crypto In The Market NowTop "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your fi...Crypto 101 Media | SponsoredA “Thank You Gift” From Pres. Trump - GeniusThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | SponsoredTop investors are backing this “unlisted” stockWhen the team that built Zillow into a $16B real estate leader launches a new company, it’s worth paying atten...Pacaso | SponsoredYou’re invited! See my NEWEST trading strategyThis could easily be the most lucrative new trading strategy of 2025... So you’re not going to want to miss...Monument Traders Alliance | SponsoredThe Great AI-Energy CollisionThe biggest players in AI and tech are desperate to bring this limitless power source online. And fast. It...Porter & Company | SponsoredTrump’s “Magic Pattern” targets stock market boomAccording to millionaire-trader Jeff Clark, President Trump's bold agenda is poised to unleash a historic trad...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akebia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
